Please assess the completion status of the following clinical trial:

Trial Title: Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have a diagnosis of GI malignancy and who are scheduled to receive their initial treatment with an oxaliplatin-containing regimen in combination with 5-fluorouracil; these include combinations such as fluorouracil, oxaliplatin, and leucovorin calcium (FOLFOX), FOLFOX + bevacizumab, FOLFOX + cetuximab~* Standard antiemetic therapy with initial treatment must include the dolasetron and dexamethasone; the minimum adequate doses include either:~  * Dolasetron (Anzemet) 100mg PO/IV or 1.8mg/kg IV AND~ * Dexamethasone (Decadron) 10mg PO/IV~* Patient must agree, as part of the informed consent, to keep a journal of the episodes of nausea, vomiting, retching, and amount of rescue medications used on days 1 to 5 (day 1 = day of treatment)~* Signed informed consent~Exclusion Criteria:~* Allergy or intolerance to dolasetron and dexamethasone~* Use of another antiemetic agent (5HT3 antagonists, phenothiazines, butyrophenones, cannabinoids, metoclopramide, or corticosteroids) within 72 hours of day 1 of the study~* An episode of vomiting or retching within 24 hours before the start of the initial treatment with oxaliplatin-containing regimen~* Severe concurrent illness other than neoplasia~* Gastrointestinal obstruction or an active peptic ulcer~* Radiation therapy to the abdomen or pelvis within 1 week before or after day 1 of the study~* Absolute neutrophil count of less than 1.5 x 10\^9/L (unless physician approves to proceed with chemotherapy) or~* Platelets less than 100 x 109/L (unless physician approves to proceed with chemotherapy)~* Total bilirubin \> 2 x upper limits of normal~* Patients who are pregnant or breast feeding~* Patients who are non-English speaking~* Patients with cancer-induced nausea and vomiting grade 1 or greater using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (aprepitant, dolasetron mesylate, dexamethasone) (Type: EXPERIMENTAL): Patients receive dolasetron mesylate PO or IV, dexamethasone PO or IV, and aprepitant PO 1 day before chemotherapy and dexamethasone PO and aprepitant PO on days 2 and 3 after chemotherapy begins during course 2-3.
- Arm II (placebo, dolasetron mesylate, dexamethasone) (Type: PLACEBO_COMPARATOR): Patients receive dolasetron mesylate and dexamethasone as in Arm I and placebo PO 1 day before chemotherapy and dexamethasone PO and placebo PO on days 2 and 3 after chemotherapy begins during courses 2-3.

Based on this trial design, predict the completion outcome and termination type (if applicable).